Clinical Results of Sodium Borocaptate (BSH)-Based Intraoperative Boron Neutron Capture Therapy (IO-BNCT)

摘要: The first clinical trials of BNCT were conducted at the Brookhaven Graphic Reactor and Medical Research during 1951 1952 Massachusetts Institute Technology from 1959 to 1962 [3]. boron compounds used boric acid borate as carrier. results discouraging: none patients survived for 1 year. Serious complications such acute brain swelling delayed cerebral necrosis resulted high content in blood normal tissue In 1968, Hatanaka introduced BSH a carrier Japan, between 1968 1998 more than 170 with malignant intracranial tumors, especially GBM, treated combination pure thermal neutron beam [4, 5, 12, 13]. For become useful treatment modality, it is crucial that be evaluated biologically clinically. outcomes favorable whose GBM located within 4-cm depth surface 5]. However, they unsatisfactory tumors situated deeper regions because fluence delivery into deep was inadequate. Therefore, epithermal developed several international institutions improve delivery. At Japan Atomic Energy (JAERI) Kyoto University (KUR) mixed beams 1998, before independent introduction beam. Use can distribution sites, which turn increases therapeutic efficacy BNCT. We have performed BSH-based intraoperative using since 1998. During irradiation, inserted gold wires are measure flux around tumor tissue. Using data obtained individual points surface, center bulk, area invasion, we analyze actual radiation dose each point. With these accurate radiation-dose data, then study course BNCT-treated patient.